O
WST icon

OrbiMed’s West Pharmaceutical WST Stock Holding History

OrbiMed’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
+70,600
New +$21.6M 0.47% 56

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

OrbiMed's WST Position: Q2 2026 in Review

OrbiMed opened a new position in West Pharmaceutical (WST) in Q2 2026: 70,600 shares worth $25.3M. The stake represents 0.47% of the portfolio and ranks #56 among its holdings.

827 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • OrbiMed held 70,600 shares of West Pharmaceutical worth $25.3M as of Q2 2026.
  • West Pharmaceutical was a new OrbiMed position in Q2 2026.
  • West Pharmaceutical made up 0.47% of OrbiMed's portfolio in Q2 2026, its #56 holding.
  • 827 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.